The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects

British Journal of Clinical Pharmacology

Volumn 81, Issue 5, 2016, Pages 878-890

  Langenickel, Thomas H ^a   Tsubouchi, Chiaki ^a   Ayalasomayajula, Surya ^b   Pal, Parasar ^c   Valentin, Marie Anne ^a   Hinder, Markus ^a   Jhee, Stanford ^d   Gevorkyan, Hakop ^d   Rajman, Iris ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c NOVARTIS HEALTHCARE PVT LTD   (India)

^d PAREXEL INTERNATIONAL   (United States)

Author keywords

amyloid ; CSF; heart failure; LCZ696; neprilysin

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 CARBOXY 1 BUTYLCARBAMOYL)PROPIONIC ACID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; PLACEBO; SACUBITRIL PLUS VALSARTAN; UNCLASSIFIED DRUG; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; BIPHENYL DERIVATIVE; MEMBRANE METALLOENDOPEPTIDASE; TETRAZOLE DERIVATIVE;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG PENETRATION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARALLEL DESIGN; POSTDURAL PUNCTURE HEADACHE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RANDOMIZED CONTROLLED TRIAL; TEMPOROMANDIBULAR JOINT DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CEREBROSPINAL FLUID; DRUG EFFECTS; HEART FAILURE; HEART STROKE VOLUME; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AMINOBUTYRATES; AMYLOID BETA-PEPTIDES; ANGIOTENSIN RECEPTOR ANTAGONISTS; BIPHENYL COMPOUNDS; BLOOD-BRAIN BARRIER; DOUBLE-BLIND METHOD; FEMALE; HEALTHY VOLUNTEERS; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NEPRILYSIN; STROKE VOLUME; TETRAZOLES; YOUNG ADULT;

EID: 84960155668     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12861     Document Type: Article

References (39)

1. Langenickel TH, Dole WP,. Angiotensin receptor-neprilysin inhbition with LCZ696: a novel approach for the treatment of heart failure. Drug Discov Today: Therap Strateg 2012; 9: e131-9.
2. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR,. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004.
3. Vardeny O, Miller R, Solomon SD,. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail 2014; 2: 663-70.
4. Haass C, Kaether C, Thinakaran G, Sisodia S,. Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med 2012; 2: a006270.
5. Saido T, Leissring MA,. Proteolytic degradation of amyloid β-protein. Cold Spring Harb Perspect Med 2012; 2: a006379.
6. Howell S, Nalbantoglu J, Crine P,. Neutral endopeptidase can hydrolyze β-amyloid(1-40) but shows no effect on β-amyloid precursor protein metabolism. Peptides 1995; 16: 647-52.
7. Takaki Y, Iwata N, Tsubuki S, Taniguchi S, Toyoshima S, Lu B, Gerard NP, Gerard C, Lee HJ, Shirotani K, Saido TC,. Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid β peptide in the brain. J Biochem 2000; 128: 897-902.
8. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC,. Identification of the major Aβ1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 2000; 6: 143-50.
9. Carson JA, Turner AJ,. β-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J Neurochem 2002; 81: 1-8.
10. Wang DS, Dickson DW, Malter JS,. β-Amyloid degradation and Alzheimer's disease. J Biomed Biotechnol 2006; 2006: 58406.
11. Baranello RJ, Bharani KL, Padmaraju V, Chopra N, Lahiri DK, Greig NH, Pappolla MA, Sambamurti K,. Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease. Curr Alzheimer Res 2015; 12: 32-46.
12. Glenner GG, Wong CW, Quaranta V, Eanes ED,. The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. Appl Pathol 1984; 2: 357-69.
13. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y,. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron 1994; 13: 45-53.
14. Iwatsubo T, Mann DM, Odaka A, Suzuki N, Ihara Y,. Amyloid beta protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in down syndrome. Ann Neurol 1995; 37: 294-9.
15. Sorrentino P, Iuliano A, Polverino A, Jacini F, Sorrentino G,. The dark sides of amyloid in Alzheimer's disease pathogenesis. FEBS Lett 2014; 588: 641-52.
16. Jarrett JT, Berger EP, Lansbury PT Jr, The C-terminus of the β protein is critical in amyloidogenesis. Ann N Y Acad Sci 1993; 695: 144-8.
17. Gaudoux F, Boileau G, Crine P,. Localization of neprilysin (EC 3.4.24.11) mRNA in rat brain by in situ hybridization. J Neurosci Res 1993; 34: 426-33.
18. Ji Y, Permanne B, Sigurdsson EM, Holtzman DM, Wisniewski T,. Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. J Alzheimers Dis 2001; 3: 23-30.
19. Betts V, Leissring MA, Dolios G, Wang R, Selkoe DJ, Walsh DM,. Aggregation and catabolism of disease-associated intra-Aβ mutations: reduced proteolysis of AβA21G by neprilysin. Neurobiol Dis 2008; 31: 442-50.
20. Lee J, Culyba EK, Powers ET, Kelly JW,. Amyloid-β forms fibrils by nucleated conformational conversion of oligomers. Nat Chem Biol 2011; 7: 602-9.
21. Benilova I, Karran E, De SB,. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 2012; 15: 349-57.
22. Vandersteen A, Masman MF, De BG, Jonckheere W, van der Werf K, Marrink SJ, Rozenski J, Benilova I, De SB, Subramaniam V, Schymkowitz J, Rousseau F, Broersen K,. Molecular plasticity regulates oligomerization and cytotoxicity of the multipeptide-length amyloid-β peptide pool. J Biol Chem 2012; 287: 36732-43.
23. Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, Ghetti B, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Salloway S, Schofield PR, Sperling RA, Marcus D, Cairns NJ, Buckles VD, Ladenson JH, Morris JC,. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med 2014; 6: 226ra30.
24. Rosen C, Hansson O, Blennow K, Zetterberg H,. Fluid biomarkers in Alzheimer's disease-current concepts. Mol Neurodegener 2013; 8: 20.
25. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O,. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69: 98-106.
26. Englund H, Anneren G, Gustafsson J, Wester U, Wiltfang J, Lannfelt L, Blennow K, Hoglund K,. Increase in β-amyloid levels in cerebrospinal fluid of children with down syndrome. Dement Geriatr Cogn Disord 2007; 24: 369-74.
27. Moro ML, Giaccone G, Lombardi R, Indaco A, Uggetti A, Morbin M, Saccucci S, Di FG, Catania M, Walsh DM, Demarchi A, Rozemuller A, Bogdanovic N, Bugiani O, Ghetti B, Tagliavini F,. APP mutations in the Aβ coding region are associated with abundant cerebral deposition of Aβ38. Acta Neuropathol 2012; 124: 809-21.
28. Molinuevo JL, Blennow K, Dubois B, Engelborghs S, Lewczuk P, Perret-Liaudet A, Teunissen CE, Parnetti L,. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 2014; 10: 808-17.
29. Mulugeta E, Londos E, Ballard C, Alves G, Zetterberg H, Blennow K, Skogseth R, Minthon L, Aarsland D,. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2011; 82: 160-4.
30. Mattsson N, Zetterberg H, Bianconi S, Yanjanin NM, Fu R, Mansson JE, Porter FD, Blennow K,. γ-secretase-dependent amyloid-β is increased in Niemann-Pick type C: a cross-sectional study. Neurology 2011; 76: 366-72.
31. Dobson CM,. The structural basis of protein folding and its links with human disease. Philos Trans R Soc Lond. B Biol Sci 2001; 356: 133-45.
32. Dobson CM,. Protein aggregation and its consequences for human disease. Protein Pept Lett 2006; 13: 219-27.
33. Rembach A, Watt AD, Wilson WJ, Villemagne VL, Burnham SC, Ellis KA, Maruff P, Ames D, Rowe CC, Macaulay SL, Bush AI, Martins RN, Masters CL, Doecke JD,. Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden. J Alzheimers Dis 2014; 40: 95-104.
34. Donohue MC, Moghadam SH, Roe AD, Sun CK, Edland SD, Thomas RG, Petersen RC, Sano M, Galasko D, Aisen PS, Rissman RA,. Longitudinal plasma amyloid β in Alzheimer's disease clinical trials. Alzheimers Dement 2014;; Oct 6: pii: S1552-5260(14)02769-1.
35. McGuinness B, Craig D, Bullock R, Malouf R, Passmore P,. Statins for the treatment of dementia. Cochrane Database Syst Rev 2014; 7: CD007514.
36. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thorton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y,. Meta-analysis of 74046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013; 45: 1452-8.
37. Debiec H, Nauta J, Coulet F, van der Burg M, Guigonis V, Schurmans T, de Heer E, Soubrier F, Janssen F, Ronco P,. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet 2004; 364: 1252-9.
38. Miller DL, Papayannopoulos IA, Styles J, Bobin SA, Lin YY, Biemann K, Iqbal K,. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys 1993; 301: 41-52.
39. Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, Mawuenyega K, Blazey T, Goate A, Chott R, Yarasheski KE, Holtzman DM, Morris JC, Benzinger TL, Bateman RJ,. Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med 2013; 5: 189ra77.